Michael Lesko, DO
Cardiovascular Disease · Port Matilda, PANPI 1124019104
Payments from drug & device makers
What this record shows
This record is dominated by education: $91 of the $91 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Esperion Therapeutics, Inc.. That places this record below the midpoint for cardiovascular disease clinicians in PA, where the typical reported total is $1,447.
Across 2 payments — averaging $45.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$91
Across 16 payments — averaging $13,236 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$123K
- Astrazeneca UK Limited$89K
What the payments were for
- Education$91100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 2 | $91 |
How this compares
$91 in reported general payments places this provider in the 5th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $145,875 |
| Repatha SureclickEvolocumab | 90 | $98,688 |
| EntrestoSacubitril/Valsartan | 26 | $38,824 |
| Praluent PenAlirocumab | 39 | $32,682 |
| Repatha PushtronexEvolocumab | 22 | $21,603 |
| Metoprolol Succinate | 208 | $4,974 |
| Amiodarone Hcl | 32 | $2,111 |
| Atorvastatin Calcium | 142 | $1,973 |
| Ezetimibe | 85 | $1,655 |
| Rosuvastatin Calcium | 67 | $1,197 |
| Losartan Potassium | 71 | $791 |
| Torsemide | 15 | $543 |
| ClopidogrelClopidogrel Bisulfate | 45 | $512 |
| Lisinopril | 66 | $490 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $439 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Port Matilda
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
- Rajesh DaveCamp Hill$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.